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Abstract
Extracellular adenosine triphosphate (ATP) is known to boost immune responses in the tumor microenvironment
but might also contribute directly to cancer cell death. CD39/ENTPD1 is the dominant ectonucleotidase expressed
by endothelial cells and regulatory T cells and catalyzes the sequential hydrolysis of ATP to AMP that is further
degraded to adenosine by CD73/ecto-5′-nucleotidase. We have previously shown that deletion of Cd39 results in
decreased growth of transplanted tumors in mice, as a result of both defective angiogenesis and heightened in-
nate immune responses (secondary to loss of adenosinergic immune suppression). Whether alterations in local
extracellular ATP and adenosine levels as a result of CD39 bioactivity directly affect tumor growth and cytotoxicity
has not been investigated to date. We show here that extracellular ATP exerts antitumor activity by directly inhibit-
ing cell proliferation and promoting cancer cell death. ATP-induced antiproliferative effects and cell death are, in
large part, mediated through P2X7 receptor signaling. Tumors in Cd39 null mice exhibit increased necrosis in as-
sociation with P2X7 expression. We further demonstrate that exogenous soluble NTPDase, or CD39 expression by
cocultured liver sinusoidal endothelial cells, stimulates tumor cell proliferation and limits cell death triggered by
extracellular ATP. Collectively, our findings indicate that local expression of CD39 directly promotes tumor cell
growth by scavenging extracellular ATP. Pharmacological or targeted inhibition of CD39 enzymatic activity may
find utility as an adjunct therapy in cancer management.
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Introduction
Adenosine triphosphate (ATP) mediates multiple physiological reac-
tions and plays a crucial role in cellular metabolism, inclusive of roles
in bioenergetics [1–3]. Extracellular ATP acts on type 2 purinergic
(P2) receptors to exert signaling effects. There are two P2 families:
seven P2X ion channel receptors recognizing ATP (P2X1-7) and eight
P2Y G protein–coupled receptors (P2Y1, 2, 4, 6, 11-14) that bind sev-
eral nucleoside triphosphates and diphosphates [4–6]. Documented
cytotoxic effects of extracellular ATP on various malignant cells have
elicited attention to this signaling pathway [2,7–10]. Five P2 recep-
tor subtypes have been considered to be involved in the antitumor
actions of ATP, namely P2X5, P2X7, P2Y1, P2Y2, and P2Y11 (exclu-
sively in human), but precise roles for these receptors are not well de-
fined [2,9,11].
Abbreviations: ATP, adenosine triphosphate; ADP, adenosine diphosphate; AMP, aden-
osine monophosphate; ENTPD1, ectonucleoside triphosphate diphosphohydrolase 1;
LSEC, liver sinusoidal endothelial cell; Treg, regulatory T cells; TLC, thin-layer chro-
matography; wt, wild type; Luc-B16/F10, luciferase-expressing B16/F10 cells
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Intracellular ATP concentrations are typically of the order of 3 to
10 mM. Basal concentrations of extracellular ATP, in contrast, are
considered to be around 10 nM. The latter levels are maintained
by ectonucleotidases, which hydrolyze released ATP sequentially to
adenosine diphosphate (ADP), adenosine monophosphate (AMP),
and further to adenosine [12]. These ectoenzymes result in a 106-fold
gradient for potential ATP efflux. Therefore, the release of a small
amount of intracellular ATP could elicit a dramatic elevation of
extracellular ATP concentration thereby affecting purinergic signal-
ing [13].
Anticancer chemotherapies directly induce tumor cell death. Dying
tumor cells release mediators that signal cellular damage (e.g., uric acid,
nucleic acids, alum, high mobility group box 1 protein) [14,15]. These
signals may be recognized by dendritic cells, which further provoke
anticancer immune responses [16–18]. ATP has been recently identi-
fied as a novel danger signal emitted by dying tumor cells and is also
released by immune cells. ATP is considered important for the effi-
cient immune responses required for the successful anticancer ther-
apies [19]. ATP can also be released from the cytosol of necrotic
cells, which are always present in the center of fast-growing tumors
[11], such as in transplanted melanomas [20,21].
CD39/ENTPD1 (ectonucleoside triphosphate diphosphohydro-
lase 1) is the dominant ectonucleotidase expressed by endothelial cells
(ECs) and regulatory T cells (Treg) [22–24]. We have previously dem-
onstrated that deletion of Cd39 results in reduction of melanoma
growth and inhibition of pulmonary metastases, associated with abro-
gation of angiogenesis [20]. We have also recently shown that CD39
expression on Treg inhibits NK cell–mediated antitumor activity and
is permissive for hepatic metastatic tumor growth, whereas vascular
CD39 boosts angiogenesis [21]. When ATP appears in the extracel-
lular space of tumor microenvironment, it is quickly metabolized by
CD39 to AMP. Therefore, in Cd39 null mice, failure of removal of
ATP released by necrotic tumor cells in the center of fast-growing tu-
mors might cause acute increases in levels of local extracellular ATP
and result in killing of adjacent tumor cells.
Given that CD39 has been implicated in promoting tumor growth
and metastases through the suppression of antitumor immune re-
sponses and enhancement of angiogenesis [20,21], we further hypoth-
esized that CD39 expression by ECs might directly protect tumor cells
from high levels of extracellular ATP (from whatever source). In this
study, we demonstrate that extracellular ATP directly limits tumor cell
growth and that these antitumor effects could be mitigated by pro-
vision of CD39/apyrase or by the intrinsic EC expression of CD39.
Targeting the expression and/or ectoenzymatic activity of CD39 in
combination with other chemotherapy regimens might provide a novel
approach to cancer therapy.
Materials and Methods
Mice
Eight- to twelve-week-old male Cd39 null and Cd73 null mice on
the C57BL/6 background (have been interbred and backcrossed ×12)
were used [23,25]. Age-, sex-, and strain-matched wild-type mice were
purchased from Taconic (Hudson, NY). All experimental mice were
kept in a temperature-controlled room with alternating 12-hour dark-
light cycles. Animal experimentation protocols were reviewed and
approved by the Institutional Animal Care and Use Committees of
Beth Israel Deaconess Medical Center.
Tumor Cell Lines
Luciferase-expressing B16/F10 (luc-B16/F10), a genetically modi-
fied C57BL/6 mouse melanoma cell line, was established as previously
described [26]. Syngeneic C57BL/6 murine MCA38 colon cancer cells
were provided by Dr Nicholas P. Restifo (National Cancer Institute).
All cell lines were tested forMycoplasma and other infections by mouse
IMPACT III PCR Profile using RADIL (Columbia, MO) and were
maintained as described previously [21].
Antibodies and Reagents
Rabbit anti-P2X7 antibodywas purchased fromAlomone Laboratories
( Jerusalem, Israel) [27,28]. Mouse anti–β-actin monoclonal antibody
was from Abcam (Cambridge, MA). The rabbit antibodies against
cleaved caspase-3 (Asp175), cleaved caspase-9 (Asp353), caspase-3
(8G10), and caspase-9 were purchased from Cell Signaling Technol-
ogy (Danvers, MA). Rat anti–mouse CD31 antibody was obtained
from R&D Systems (Minneapolis, MN). The production of rabbit
polyclonal anti–mouse CD39 antibody (C9F) has been described previ-
ously [29]. 3H-thymidine was purchased from Perkin-Elmer (Waltham,
MA). All chemicals were obtained from Sigma-Aldrich (St Louis,
MO), unless otherwise stated.
Assessment of Cell Proliferation and Cell Viability
Cells (5 × 103) were seeded into 96-well plates and cultured for
24 hours. Nucleotides were then added into cultures. Sixteen hours
later, cell viability was analyzed using Cell Counting Kit-8 (Dojindo
Molecular Technologies, Inc, Rockville, MD) following the manufac-
turer’s instructions. In parallel, 3H-thymidine (1 μCi/well) was added
into the cultures immediately after addition of nucleotides, and cell
proliferation was evaluated 16 hours later using 3H-TdR incorpora-
tion method as described previously [30].
In Situ Cellular Analysis
Cells (5 × 103) were seeded into Corning 3603 Black 96-well plates
and cultured for 24 hours before being exposed to ATP. Sixteen hours
later, cell growth was evaluated using the Celigo Cytometer (Cyntellect,
Inc, San Diego, CA). Cells were imaged and counted using the Celigo
Cell Counting application.
Liver Sinusoidal Endothelial Cell Culture
Liver sinusoidal endothelial cells (LSECs) were isolated, and cell pu-
rity was assayed using acetylated low-density lipoprotein labeled with
1,1′-dioctadecyl-3,3,3′3′-tetramethylindo-carbocyanine perchlorate
(10 μg/ml) following the manufacturer’s instructions (Biomedical
Technologies, Inc, Stoughton, MA) as previously described [31,32].
The purity of LSECs was greater than 99%.
Cotreatment or Coculture Experiments
For experiments with apyrase or antagonist treatment, luc-B16/F10
cells were pretreated with apyrase, KN-62 (Tocris Bioscience, Ellisville,
MO), MRS-2500, or suramin for 30 minutes before being exposed to
treatment of ATP. For coculture experiments, LSECs were seeded to-
gether with luc-B16/F10 cells (3 × 103) at indicated ratios of cell
numbers into fibronectin-coated plates and cultured in 1:1 mixtures
of LSEC medium and luc-B16/F10 medium for 24 hours before being
exposed to further treatments.
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Immunoblot Analysis
Cultured cells were lysed inmodified RIPA buffer containing 50mM
Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% sodium deoxycholate,
0.1% SDS, 1% NP-40, phosphatase inhibitors (Sigma-Aldrich), and
protease inhibitor cocktail tablets (Roche Applied Science, Mannheim,
Germany). The measurement of protein concentrations and detailed
procedures of immunoblot analysis were described previously [33].
Reverse Transcription–Polymerase Chain Reaction and
Real-time Quantitative PCR
Total RNA were extracted and purified from cells using an RNeasy
kit (Qiagen, Valencia, CA). Reverse transcription was conducted on
1 μg of total RNA using ABI Prism TaqMan reverse transcription re-
agents (Applied Biosystems, Foster City, CA). Reverse transcription–
polymerase chain reaction (RT-PCR) and real-time quantitative PCR
(RQ-PCR) analyses were performed as described previously [33,34].
Specific primers for RT-PCR were obtained from Invitrogen (Carlsbad,
CA), and the primer sequences were shown in Table W1. Primer probe
sets of P2X7 and GAPDH used for RQ-PCR were purchased from
Applied Biosystems.
Flow Cytometric Analysis
After treatment of luc-B16/F10 cells with ATP or together with
KN-62 for the indicated periods, apoptotic cells and necrotic cells
were analyzed by staining the cells with fluorescein isothiocyanate
(FITC)–annexin V and propidium iodide (PI), according to the manu-
facturer’s instructions (apoptosis kit; BD Pharmingen, San Diego, CA).
Briefly, an aliquot of 105 cells was incubated with FITC–annexin V
and PI for 15 minutes at room temperature in the dark. Cells were
then immediately analyzed by LSR II (BD Biosciences). Viable cells
are not stained with FITC–annexin V or PI. The necrotic cells were
FITC–annexin V and PI-positive, whereas apoptotic cells were an-
nexin V–positive and PI-negative [35,36]. FACS data were analyzed
using FlowJo software (TreeStar, Inc, Ashland, OR).
Tumor Supernatant Preparation
Luc-B16/F10 cells (5 × 105) were injected (s.c.) into flanks of wild-
type C57BL/6 mice as previously established [20]. On day 14, tumors
were separated, weighed, excised, and washed once with complete
RPMI 1640 medium. Media were collected as “prewash” media.
The tumor tissues supplemented with fresh media were then passed
through a 100-μm cell strainer. The filtrates were then subjected to
snap-freeze (in liquid nitrogen)–thaw cycles (twice to disrupt cell
membranes), followed by centrifugation at 14,000 rpm for 30 minutes
at 4°C. Supernatants were collected as “tumor supernatants” and im-
mediately added into luc-B16/F10 cell cultures.
Measurement of ATP Levels in Biologic Samples
The “prewash” media and “tumor supernatants” were subjected to
a deproteinizing sample preparation kit (BioVision, Mountain View,
CA) to remove the proteins, followed by assays of ATP levels using
the ATP Colorimetric/Fluorometric Assay Kit (BioVision) in accor-
dance with the manufacturer’s instructions.
Hepatic Metastatic Melanoma Model
This was preformed as described previously [21]. Briefly, luc-B16/
F10 cells (2 × 105) were infused into liver through portal vein of
C57BL/6 mice. After 14 days, the mice were killed and examined for
tumor growth in the liver.
Immunocytohistochemistry and Immunofluorescence
These procedures were performed as previously [20,21,33,37]. Luc-
B16/F10 cells (1 × 103) were seeded on poly-D-lysine/laminin–coated
glass coverslips (BD Biosciences) and cultured for 4 days before being
exposed to treatment.
Thin-Layer Chromatography Analysis
Enzymatic activity of freshly isolated LSECs or luc-B16/F10 cells
was analyzed using thin-layer chromatography (TLC), as previously
described [30,34]. A total of 3 × 105 cells were analyzed.
Statistical Analysis
All data are represented as means ± SD of values (obtained from at
least three independent experiments in triplicates). All histologic and
immunohistochemical images are representative of at least four mice
per group. All statistical analyses were performed using the 2-tailed
Student’s t test. Significance was defined as P < .05.
Results
Antiproliferative Functions of ATP Are Mediated through
P2X7 Receptor
Luc-B16/F10 cells were used for the present study. We first exam-
ined the effects of extracellular ATP at high concentrations on the
proliferation of these B16 melanoma cells. As shown in Figure 1A,
cell proliferation was inhibited by exposure (16 hours) of ATP in a
concentration-dependent manner. BzATP (synthetic nonhydrolyz-
able and potent ATP analogue) had more potent inhibitory effects
on melanoma cell proliferation (Figure 1B), as expected. Similar in-
hibitory effects of extracellular ATP on other MCA38 colon cancer
cells were also observed, albeit with differential dose-response curves
(Figure W1).
To investigate involvement of P2 receptor(s) in the effects on ATP-
induced proliferation, we first examined mRNA expression of all P2
receptors by RT-PCR analysis using total RNA from luc-B16/F10
cells (Figure 1C). Luc-B16/F10 cells expressed mRNA of several P2
receptors but not P2X6, P2Y4, and P2Y11.
It has been recently reported that P2X7 and P2Y1 might be the
major P2 receptors responsible for the antimelanoma activity of
ATP in human cells [38]. Next, therefore luc-B16/F10 cells were in-
cubated with P2 antagonists including KN-62 (to P2X7), MRS-2500
(to P2Y1), and suramin (nonselective to P2Rs), together with ATP
(2.5 mM) for 16 hours. Changes in cell proliferation were then eval-
uated. Coincubation of cells with KN-62 decreased the extent of
ATP-induced inhibition on melanoma cell proliferation in a dose-
dependent manner (60% at 1 μM and 70% at 2.5 μM) with noted
cytotoxicity of 2.5 μM KN-62 alone (Figure 1D). MRS-2500 (Fig-
ure 1E ), or suramin (data not shown), failed to block the inhibitory
effects of ATP.
We next performed Western blot analysis using total cell lysates
from luc-B16/F10 cells to examine the protein expression of P2X7
in these cells. For comparison, a human embryonic kidney (HEK293)
cells line, which does not express P2X7 [39], was also tested as a nega-
tive control. As shown in Figure 1F, P2X7 was expressed in luc-B16/
F10 cells. Taken together, our data suggest that P2X7 receptor medi-
ates, at least in part, the antiproliferation action of ATP in B16 mela-
noma cells.
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Figure 1. Antiproliferative effects of ATP on B16 melanoma cells are mediated through the P2X7 receptor. High levels of extracellular
ATP and BzATP inhibited melanoma cell proliferation in a dose-dependent manner. (A and B) Luc-B16/F10 cells were treated with ATP
(A) or BzATP (B) at the indicated concentrations for 16 hours, and cell proliferation was determined by 3H-TdR incorporation assay.
Columns indicate mean of triplicate determinations; bars, SD. (C) mRNA expression of P2 receptors in luc-B16/F10 cells were deter-
mined by RT-PCR. The PCR products were visualized by agarose gel electrophoresis. The size standards (Std) are shown in the left lane.
(D and E) Luc-B16/F10 cells were exposed to antagonists of P2Rs (KN-62, selective for P2X7; MRS-2500, selective for P2Y1), at indicated
concentrations, in the presence or absence of ATP (2.5 mM) for 16 hours. Cell proliferation was assessed by 3H-TdR incorporation and
indicated as a percentage of untreated control cells. Points indicate mean of triplicate determinations; bars, SD. (F) Immunoblot analysis
of the P2X7 expression in luc-B16/F10 cells. A sample of total cell lysates (20 μg of protein) from luc-B16/F10 cells was run in parallel with
a sample of HEK293 cell lysates (20 μg, negative control) and probed with P2X7 antibody (top). β-Actin was used as loading control
(bottom). Size standards are shown in the left lane.
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ATP Promotes Tumor Cell Death through P2X7 Receptor
Besides inhibition of cell proliferation, other mechanisms for anti-
tumor function of ATP include direct induction of cell death. Dra-
matic decreases in cell growth caused by ATP may be also associated
with cell death. We next examined the cell death after ATP exposure
(Figure 2). ATP induced cytotoxicity on melanoma cells (Figure 2A).
In situ cellular analysis demonstrated that melanoma cell death (Fig-
ure 2, B-D) with decreases in cell confluency and cell count was trig-
gered on ATP stimulation, in a dose-dependent manner.
Similar effects were observed in MCA38 colon cancer cells albeit
with different sensitivity to ATP (Figure W2 and data not shown), in
keeping with data shown in Figure W1.
To precisely examine patterns of apoptosis and necrosis in the set-
ting of ATP-induced cell death, the staining pattern of the cells were
Figure 2. ATP-induced B16 melanoma cell death. Luc-B16/F10 cells were treated with ATP at the indicated concentrations for 16 hours.
(A) Cell viability was measured using Cell Counting Kit-8. Cells were also imaged and counted using the Celigo Cell Counting application.
(B) Representative brightfield images of live luc-B16/F10 cells. (C) Confluency of cells per well is expressed as a percentage of untreated
control cells (left). Representative image of control cells with gating of confluency is shown on the right. (D) Cell count per well. Columns
indicate mean of triplicate determinations; bars, SD.
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analyzed with fluorescein isothiocyanate (FITC)–conjugated annexin V
and PI by flow cytometry [35,36]. In this experiment, luc-B16/
F10 cells treated with ATP (2.5 mM) alone or together with KN-62
(2.5 μM), or MRS-2500 (2.5 μM), or suramin (250 μM) were stained
simultaneously with both FITC–annexin V and PI. Induction of
both apoptosis and necrosis were observed in cells exposed to ATP in
a time-dependent manner (Figure 3A, top). In addition, ATP-stimulated
apoptotic/necrotic cell death could be blocked by coincubation with
a P2X7 antagonist, KN-62 (2.5 μM; Figure 3A, bottom), but not by
coincubation of MRS-2500 or suramin (data not shown).
Next, we tested the cleavage of caspase-3 and caspase-9 as markers
of apoptosis. Figure 3B showed that the levels of cleaved caspase-3
(Figure 3B, top), and caspase-9 (Figure 3B, bottom) increased over time
after exposure to ATP. These observations were further confirmed by
Western blot analysis using anti–cleaved caspase-3 and caspase-9 anti-
bodies (Figure 3C , left). Furthermore, coincubation of cells with KN-62
(2.5 μM) blocked ATP-induced cleavage of caspase-3 and caspase-9
(Figure 3C , right).
Quantitative real-time PCR revealed that treatment with ATP
(2.5 mM) for 16 hours significantly increased the mRNA expression
level of P2X7, whereas cotreatment with KN-62 (2.5 μM) abrogated
the increase in P2X7 expression (Figure 3D). These findings indicate
that ATP-induced cell death in B16 melanoma cells is associated with
both apoptosis and necrosis and is at least partly mediated through
the P2X7 receptor.
Apyrase (Soluble NTPDase) or Vascular Cell CD39 Expressed
by LSECs Abrogates/Reverses Antitumor Activity of ATP
Next, we sought to determine whether scavenging of extracellular
ATP by apyrase, a soluble form of NTPDase with ATPase and ADPase
activity at a 1:1 ratio, could rescue ATP-stimulated growth inhibition
of tumor cells. Figure 4A showed that tumor cell growth inhibition
triggered by ATP (2.5 mM) was completely abrogated by coincubation
of cells with apyrase (10 U/ml). The rescue of tumor cells by apyrase
was dose dependent.
CD39 and CD73 are the major ectonucleotidases expressed by
LSECs. Next, LSECs were purified from wt, Cd39 null, or Cd73 null
livers and were cocultured with luc-B16/F10 cells for 24 hours, at
various ratios of cell numbers, before being exposed to ATP (2.5 mM)
for 16 hours.
Successful isolation of healthy LSECs was verified by uptake of
DiI-labeled Ac-LDL and FACS analysis for endothelium makers (in-
cluding CD31, CD34, and Flk-1) (data not shown), as established
previously [31,32].
As shown in Figure 4B, wt LSECs attenuated the inhibitory effects
of ATP on tumor cell growth, whereas Cd39 null LSECs did not
retain this capacity. Interestingly, growth inhibition by ATP was re-
versed by Cd73 null LSECs to a greater extent, when compared with
wt LSECs (Figure 4B). The rescue observed with wt and Cd73 null
LSECs was dose dependent.
We also noted that extracellular ATP inhibited growth of LSECs
(Figure W3 for wt cells and data not shown for null cells).
To further investigate the mechanisms underlying the observations
in Figure 4B, purine metabolism by ectonucleotidase activity of freshly
isolated LSECs was examined by TLC analysis using ADP-C14 as sub-
strate. ADP was first hydrolyzed to AMP and then to adenosine by
wt LSECs. Adenosine was further degraded to hypoxanthine by wt
LSECs (Figure 4C ). Cd73 null LSECs could only generate AMP
but not adenosine (Figure 4C ). Cd39 null LSECs and luc-B16/F10
cells had minimal nonspecific ectonucleotidase activity, in contrast to
wt LSECs (Figure 4C). These findings clearly explain how wt, Cd73
null, and Cd39 null LSECs exhibit differential salvage abilities on
ATP-induced growth inhibition as observed in Figure 4B.
Defective Angiogenesis Is Associated with Heightened Tumor
Necrosis and Increased P2X7 Expression in Cd39 Null
Tumor-Bearing Mice
Wenext determined whether injured tumor cells could release endog-
enous mediators that directly result in cellular damage of contiguous/
adjacent tumor cells. Luc-B16/F10 cells were injected (s.c.) into
flanks of wild type C57BL/6 mice for 14 days, tumors were excised,
and tumor supernatants were prepared (see Materials and Methods),
these were then added to luc-B16/F10 cell cultures. In Figure 5A, we
show that melanoma cell proliferation was inhibited by the addi-
tion of tumor supernatants in a concentration-dependent manner.
Dramatic increases in ATP levels were also noted in these tumor
supernatants compared with the prewash media (Figure W4). How-
ever, coincubation with apyrase alone failed to rescue the growth in-
hibitory effects triggered by these crude tumor supernatants (data not
shown) as previously noted with exogenous ATP (Figure 4A). These
data suggest that other cytotoxic constituents besides nucleotides
contribute to the tumor killing activity of supernatants.
We have recently demonstrated the effect of Cd39 deletion on mel-
anoma growth in vivo using a murine model of hepatic metastases
of B16/F10 melanoma [21]. We noted that immune cell as well as
vascular CD39 expression promote tumor growth, whereas pharma-
cological inhibition of CD39 enzymatic activity (in contrast) abrogates
tumor growth [21].
We stained these liver tumor sections using anti-CD31 (a marker for
endothelium) and anti-CD39 antibodies. We observed that CD39 was
expressed on tumor-associated endothelial cells (ECs) in wt livers. In
contrast, in Cd39 null tumor-bearing livers, lack of CD39 expression
(suggesting decreased ATP scavenging in the tumor microenvironment)
was associated with defective angiogenesis and larger areas of necrosis
within the centers of tumors (Figure 5B). Immunofluorescent staining
on tumor sections further showed that protein expression of P2X7 was
increased on melanoma cells in Cd39 null tumor-bearing livers com-
pared with wt livers (Figure 5C).
Discussion
The present study clearly demonstrates that tumor-derived mediators,
inclusive of ATP, directly exert growth inhibitory effects on tumor cells.
The P2X7 receptor is functionally expressed in B16/F10 melanoma
cells and is responsible, at least in part, for such ATP-induced growth
inhibition and cell death. Importantly, coculture of tumor cells with
LSECs demonstrates that expression of ecto-enzyme CD39 by endo-
thelial cells counteracts tumoricidal actions stimulated by extracellu-
lar ATP. Collectively, in light of ATP-induced tumor suppression, our
results indicate novel purinergic mechanisms implicated in tumor biol-
ogy: 1) danger signals (including ATP) released by necrotic tumor cells
result in subsequent death of neighboring tumor cells and 2) CD39
expressed on ECs promotes tumor cell growth by scavenging extracel-
lular ATP in the tumor microenvironment.
Different P2 receptor subtypes have been shown to modulate dif-
ferent cellular functions such as proliferation, differentiation, and ap-
optosis. P2Y1 and P2X7 receptors are expressed in human melanoma
cells in situ and mediate apoptotic and necrotic actions of ATP [38].
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The antitumor actions of these receptors contain three processes: in-
hibition of cell proliferation, promotion of cell differentiation (result-
ing in inhibition of cell proliferation), and cell death [2]. Here, we
show that antitumor activity of ATP is largely due to the combina-
tion of inhibition of cell proliferation and induction of cell death.
These two processes are both mediated largely through the expression
of P2X7.
When ATP appears in the extracellular space of tumor microen-
vironment, this mediator is rapidly hydrolyzed by ectonucleotidases
to ADP, AMP, and, finally, adenosine [12]. Most studies to date
212 ATP and Tumor Growth Feng et al. Neoplasia Vol. 13, No. 3, 2011
Figure 4. Apyrase (soluble NTPDase) or CD39 expression on LSECs abrogates the inhibitory effects of ATP on B16melanoma cell growth. (A)
InhibitoryeffectsofATParealleviatedbyadditionof apyrase. Luc-B16/F10cellswere treatedwithapyraseat indicatedconcentrations for30min-
utes and then exposed to ATP (2.5 mM). Sixteen hours later, cell proliferation was analyzed by 3H-TdR incorporation assay and expressed as a
percentage of untreated control cells. Points indicate mean of triplicate determinations; bars, SD. (B) LSECs were isolated from C57BL/6 wild
type (wt),Cd39null, andCd73nullmice andwere coculturedwith Luc-B16/F10 cells (3×105) at the indicated ratios of cell numbers for 24 hours
before being exposed to ATP (2.5mM). Cell proliferationwas assayed and expressed as a percentage of untreated control cells. Points indicate
meanof triplicatedeterminations; bars, SD. *P<.05, **P=.002. (C) Freshly purified LSECsor luc-B16/F10cells (3×105 cells per cell type)were
subjected to TLC analysis for assessment of NTPDase activity. [C14]ADP, [C14]AMP, and [C14]ADO incubated in PBS served as standards.
Figure 3. ATP-induced apoptosis/necrosis of B16 melanoma cells is mediated through P2X7 receptor. Time course of ATP-induced cell
death in luc-B16/F10 cells is shown. The cells were exposed to 2.5 mM of ATP or in combination with KN-62 (2.5 μM) for the indicated
periods. (A) Time course of ATP-induced apoptosis and necrosis of luc-B16/F10 cells. FITC–Annexin V/PI staining of luc-B16/F10 cells
was assessed by flow cytometry at indicated times. The gates are defined as follows: I (lower left), viable; II (middle), apoptotic; and III
(upper), necrotic. (B) Cells were fixed and stained with anti–cleaved caspase-3 or caspase-9 antibodies. Cleaved caspase-3 and caspase-9
were visualized by fluorescent microscopy. Representative images for each time point. Scale bar, 100 μm. The cleavage of caspase-3 and
caspase-9 (red) were elevated in the cytoplasm aswell as in the nuclei (blue, Hoechst dye 33258) in a time-dependentmanner. (C) Cells were
harvested, lysed, and used for immunoblot analysis of cleavage of caspase-3 (top) and caspase-9 (middle). Twenty micrograms of protein
was loaded per lane, and gel loading was normalized by β-actin (bottom). (D) RQ-PCR analysis of P2X7 mRNA expression in luc-B16/F10 cells
after treatment. Columns indicate mean of triplicate determinations; bars, SD. *P = .01, **P = .001, ***P = .002.
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have focused on the alterations of purinergic receptors in tumors,
whereas ectonucleotidases are much less investigated. Purinergic sig-
naling can be modulated by modifying the expression and/or ac-
tivity of these ectoenzymes in addition to changes in P2 receptor
levels [11,40].
This study shows for the first time that deletion of Cd39 on ECs
enhances antitumor activity of ATP, whereas deletion of Cd73 on ECs
has different effects. These data suggest a feasible approach to augment
anticancer therapy by modulating expression and/or enzymatic activ-
ity of NTPDase-type ectonucleotidases. This approach might be easier
to achieve and more efficacious than to independently target several
purinergic receptors.
CD39 is also expressed by immune cells inclusive of Treg (CD4+
Foxp3+) and memory cells (CD4+CD44+CD62L−Foxp3−) [21,41].
These cells often infiltrate into solid tumors [21]. Whether these
CD39+ infiltrating immune cell populations also contribute to degra-
dation of cytotoxic ATP in the tumor microenvironment and thereby
independently promote tumor growth remains unclear.
Exposure of ECs to elevated levels of ATP has been shown to pro-
mote apoptosis in vitro [42]. We have previously demonstrated that
inhibition of tumor growth in Cd39 null mice is associated with de-
fects of tumor angiogenesis [20,21]. Moreover, in this study, we show
that ATP also exhibits direct growth inhibitory effects on LSECs (Fig-
ure W3 and data not shown) that further compromises cell-associated
NTPDase activity. Therefore, the reduction of tumor size and volume
in Cd39 null tumor-bearing mice might result from dual actions of
ATP on tumor cells as well as on ECs.
The phosphohydrolysis of ATP to adenosine has a complex mod-
ulatory effect on tumor cell proliferation and growth [43–45]. Aden-
osine ultimately derived from ATP may be responsible for some of
the observed effects as this nucleoside has been shown to affect tumor
growth in a cell-specific manner determined by concentrations and
kinetics of exposure [43–45] (and unpublished observations in our
laboratory). Tumor cell expressions of A2A and A2B have been shown
to be proapoptotic and have antitumor activity [44,45]. The actions of
A3 are contradictory. Most studies have demonstrated that A3 agonists
induce apoptosis and tumor growth inhibition [45–48], whereas
others show that A3 stimulation blocks A2A-induced cell death and
ensures cell survival [43].
Therefore, the ambient vascular nucleotide/nucleoside milieu as
regulated by ectonucleotidases and ectonucleotidases dictates the ef-
ficacy of antitumor activity of ATP in vivo. In this study, the differ-
ential salvage abilities on ATP-triggered tumor cell growth inhibition
and NTPDase activity exhibited by wt, Cd73 null, and Cd39 null
LSECs (Figure 4, B and C) are indicative of the participation of ATP-
derived adenosine in the antitumor function of ATP.
Dzhandzhugazyan et al. [49] have shown that CD39 is the major
ectonucleotidase in human melanocytes and melanoma cell lines and
CD39 is overexpressed in differentiated human melanomas. It has
been recently reported that CD73 is expressed on various tumor cells
(e.g., ID8 ovarian cancer cells) and participates in adenosine genera-
tion, thereby suppressing antitumor immune responses [50], but po-
tentially also affecting cancer cell apoptosis.
We therefore also examined the expression of CD39 and CD73
on tumor cells used for this study. Neither CD39 nor CD73 expres-
sion was observed on cultured B16/F10 or MCA38 cells as well as
on malignant cells in metastatic tumors in the livers and lungs at any
progression stage after tumor challenge [20,21] (data not shown).
Lastly, we have also shown that ATP exhibits cytotoxic effects on
MCA38 colon cancer cells as well, suggesting general feature of anti-
tumor capability of ATP (Figures W1 and W2; data not shown).
In summary, we postulate an intriguing mechanism by which ex-
tracellular ATP released by dying tumor cells accumulates to high
concentrations that not only function as danger signals to the im-
Figure 5.Metastatic melanoma growth in Cd39 null mice. (A) Dose-
dependent inhibitory effects of tumor supernatants (16 hours of
treatment) on luc-B16/F10 melanoma cell proliferation. (B) Repre-
sentative immunohistochemical staining on tumor tissue sections
obtained from melanoma metastasized to mouse livers using anti-
CD31 (a marker for endothelium) and anti-CD39 antibodies and
TUNEL staining (TdT) for apoptosis. (C) P2X7 expression on tumor
tissues. Representative fluorescence immunohistochemical stain-
ing using anti-P2X7 antibody: Hoechst dye 33258 staining nuclei
in blue and P2X7 in red. Columns indicate mean of triplicate deter-
minations; bars, SD. Scale bar, 100 μm.
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mune system but also can directly kill adjacent tumor cells. Our data
showing that the antitumor activities of ATP are dose-dependent and
can be amplified by inhibition of ectonucleotidase, such as CD39,
open new avenues for investigation in cancer management.
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Table W1. RT-PCR Primers.
Transcript Primer Sequence
Mouse P2X1 Forward 5′-tcattgccagaggctttc-3′
Reverse 5′-gtggagggttgtatgtgt-3′
Mouse P2X2 Forward 5′-caaagcctatgggattcg-3′
Reverse 5′-cctatgaggagttctgtt-3′
Mouse P2X3 Forward 5′-gtgaaaagctggaccattgg-3′
Reverse 5′-gctgccattctccatcttgt-3′
Mouse P2X4 Forward 5′-tacgtcattgggtgggtgtt-3′
Reverse 5′-cttgatctggatacccatga-3′
Mouse P2X5 Forward 5′-aggacattgacacttccctg-3′
Reverse 5′-catcaggtcacggaactcta-3′
Mouse P2X6 Forward 5′-gtggtagtctacgtgatagg-3′
Reverse 5′-gcctctctatccacatacag-3′
Mouse P2X7 Forward 5′-cttgccaactatgaacgg-3′
Reverse 5′-cttggcctttgccaactt-3′
Mouse P2Y1 Forward 5′-ttatgtcagcgtgctggtgt-3′
Reverse 5′-cgtgtctccattctgcttga-3′
Mouse P2Y2 Forward 5′-gaggacttcaagtacgtgct-3′
Reverse 5′-acggagctgtaagccacaaa-3′
Mouse P2Y4 Forward 5′-aacaactgcttcctccct-3′
Reverse 5′-aagtcctagaggtaggtg-3′
Mouse P2Y6 Forward 5′-cctgatgtatgcctgttcac-3′
Reverse 5′-cacagccaagtaggctgtct-3′
Human P2Y11* Forward 5′-tgtggcccatactggtggttgag-3′
Reverse 5′-gaagaaggggtgcacgatgccca-3′
Mouse P2Y12 Forward 5′-atatgcctggtgtcaacacc-3′
Reverse 5′-ggaatccgtgcaaagtggaa-3′
Mouse P2Y13 Forward 5′-tgcagggcttcaacaagtct-3′
Reverse 5′-cctttccccatctcacacat-3′
Mouse P2Y14 Forward 5′-ggaacaccctgatcacaaag-3′
Reverse 5′-tgaccttccgtctgactctt-3′
Mouse actin Forward 5′-tgtacgtagccatccaggct-3′
Reverse 5′-ggtaccaccagacaacactgt-3′
*Human P2Y11 was used as a negative control as mouse cells do not express P2Y11 receptor.
Figure W1. Effects of extracellular ATP on colon cancer cell prolif-
eration. Extracellular ATP inhibited proliferation of colon cancer
cells, in a dose-dependent manner. MCA38 cells were treated with
ATP at the indicated concentrations for 16 hours. Cell proliferation
was determined by 3H-TdR incorporation assay. Columns indicate
mean of triplicate determinations; bars, SD.
Figure W2. Effects of extracellular ATP on viability of colon cancer
cells. Extracellular ATP exhibited cytotoxicity on colon cancer cells
in a dose-dependent manner. MCA38 cells were treated with ATP
at the indicated concentrations for 16 hours, and cell viability was
evaluated using Cell Counting Kit-8. Columns indicate mean of trip-
licate determinations; bars, SD.
Figure W3. Effects of extracellular ATP on growth of wt LSECs.
Extracellular ATP exhibited inhibitory effects on wt LSECs in a
dose-dependent manner. Freshly purified wt LSECs were cultured
for 24 hours before being exposed to ATP at the indicated concen-
trations for additional 16 hours. (A) Cell viability was evaluated
using Cell Counting Kit-8. (B) Cells were counted using the Celigo
Cell Counting application. Columns indicate mean of triplicate de-
terminations; bars, SD.
Figure W4. Release of ATP by damaged tumor cells. Extracellular
ATP levels in prewash media (Pre-wash) and tumor supernatants
(Tumor s/n) weremeasured using the ATP Colorimetric/Fluorometric
Assay Kit (BioVision) and expressed as fold changes to the prewash
medium. Columns indicate mean of triplicate determinations; bars,
SD. *P = 3.6e − 08.
